Eliana Merle
Stock Analyst at UBS
(1.89)
# 3,014
Out of 4,734 analysts
70
Total ratings
29.41%
Success rate
-3.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $65 → $71 | $40.29 | +76.22% | 2 | Jan 8, 2025 | |
| MRNA Moderna | Maintains: Buy | $108 → $96 | $34.06 | +181.86% | 5 | Jan 8, 2025 | |
| ASND Ascendis Pharma | Initiates: Buy | $196 | $128.13 | +52.97% | 1 | Jan 7, 2025 | |
| TYRA Tyra Biosciences | Initiates: Buy | $28 | $16.19 | +72.95% | 1 | Jan 7, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $12 | $4.39 | +173.35% | 1 | Nov 12, 2024 | |
| IVA Inventiva | Initiates: Neutral | $3 | $2.16 | +38.89% | 1 | Nov 12, 2024 | |
| ALT Altimmune | Initiates: Buy | $26 | $6.86 | +279.01% | 1 | Nov 12, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $74 | $40.61 | +82.22% | 2 | Nov 4, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $411 → $441 | $293.64 | +50.18% | 3 | Nov 1, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $104 → $106 | $61.53 | +72.27% | 1 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $15.85 | +108.20% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $111.93 | +17.04% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $2 | $1.20 | +66.67% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $83 | $29.94 | +177.27% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $246.27 | +16.94% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $2.24 | +123.21% | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $33.79 | +39.09% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $7.17 | -30.26% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $4.43 | +306.32% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $42 | $25.14 | +67.06% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $25 | $6.31 | +296.20% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $14.05 | +198.93% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 | $4.10 | +339.02% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.96 | +731.69% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.66 | +289.04% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $7.37 | +537.72% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $9.41 | +70.03% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $123 | $18.05 | +581.44% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $23.76 | +463.97% | 3 | Aug 19, 2020 |
Revolution Medicines
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $40.29
Upside: +76.22%
Moderna
Jan 8, 2025
Maintains: Buy
Price Target: $108 → $96
Current: $34.06
Upside: +181.86%
Ascendis Pharma
Jan 7, 2025
Initiates: Buy
Price Target: $196
Current: $128.13
Upside: +52.97%
Tyra Biosciences
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $16.19
Upside: +72.95%
Sagimet Biosciences
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $4.39
Upside: +173.35%
Inventiva
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $2.16
Upside: +38.89%
Altimmune
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $6.86
Upside: +279.01%
Kymera Therapeutics
Nov 4, 2024
Maintains: Buy
Price Target: $80 → $74
Current: $40.61
Upside: +82.22%
Madrigal Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $411 → $441
Current: $293.64
Upside: +50.18%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Buy
Price Target: $104 → $106
Current: $61.53
Upside: +72.27%
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $15.85
Upside: +108.20%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $111.93
Upside: +17.04%
Sep 9, 2024
Maintains: Neutral
Price Target: $10 → $2
Current: $1.20
Upside: +66.67%
Aug 9, 2024
Maintains: Buy
Price Target: $85 → $83
Current: $29.94
Upside: +177.27%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $246.27
Upside: +16.94%
Jun 20, 2024
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.24
Upside: +123.21%
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $33.79
Upside: +39.09%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $7.17
Upside: -30.26%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $4.43
Upside: +306.32%
Mar 5, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $25.14
Upside: +67.06%
Oct 12, 2023
Maintains: Buy
Price Target: $36 → $25
Current: $6.31
Upside: +296.20%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $14.05
Upside: +198.93%
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $4.10
Upside: +339.02%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $0.96
Upside: +731.69%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $5.66
Upside: +289.04%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $7.37
Upside: +537.72%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $9.41
Upside: +70.03%
May 21, 2021
Initiates: Buy
Price Target: $123
Current: $18.05
Upside: +581.44%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $23.76
Upside: +463.97%